Lupus
Market Research Report by Type (Systemic Lupus Erythematosus, Neonatal Lupus,
Others), Treatment (NSAIDS, Corticosteroid, Antimalarial Drug, Biologics,
Other), End User (Hospital & Clinics, Diagnostic Laboratories, Others), and
Region-Global Forecast till 2023
As
of 2017, the market valuation of Lupus stood at USD 1.48 billion. However, as
per the latest studies, the global Lupus Market is projected to grow significantly during the forecast period with a CAGR of 11.2%. Lupus
is a chronic autoimmune disease which occurs when the immune system attacks the
healthy cells and tissues of the body, thereby causing inflammation, pain,
swelling, and damage throughout the body. Many people have an inherit tendency towards developing or
attaining lupus, which can be triggered
due to certain drugs, infections, or even sunlight. The prevalence of this
condition has prompted Market Research Future (MRFR) to take notice and study
the global market of the same.
Various
factors such as the growing prevalence of lupus diseases, increasing R&D
activities, and continuing medical advancements
for the treatment of systemic lupus erythematosus are all identified as
key factors driving the growth of the market. Also, the market involves a number of noteworthy companies that are
involved in the development of new products and product launches. However,
irrespective of the market drivers, constraints such as strict government
regulation and rising prices of lupus drugs can severely hamper its market
growth during the review period.
Market Segmentation
The
lupus market segmentation is done on the basis of treatment, end-user, and types.
By
treatment, the market includes antimalarial drugs, corticosteroids,
nonsteroidal anti-inflammatory drugs (NSAIDs), biologics, immunosuppressants,
and others.
By
end-user, the market divides into diagnostic laboratories, hospitals and
clinics, and others.
Lastly,
by type, the market comprises cutaneous lupus erythematosus, systemic lupus
erythematosus, neonatal lupus, and drug-induced lupus erythematosus. The lupus
erythematosus market segment is projected to hold the largest market percentage
due to the increasing prevalence of such diseases and the increasing drug
development over the years.
Regional Analysis
The
global lupus market is geographically segmented
into the following regions: Americas, Asia Pacific, Europe, and the Middle East
& Africa.
The
Americas is anticipated to be the most dominant regional market due to a number of factors. This includes the growing prevalence of lupus diseases, rising
demand for better treatment options, favorable government initiatives, and the
availability of reimbursement. In addition to these, the established healthcare
infrastructure facility coupled with the accessibility to biologics are also
expected to propel the market growth of this region.
The
European market is believed to hold the second-largest market position
following the Americas. The growth of the market herein is attributed to the
expanding R&D activities and widespread
prevalence of lupus diseases.
The Asia-Pacific region is expected to be the fastest-growing regional market. This can be attributed to the
growing healthcare sector, the rising incidences of lupus diseases, and
increasing regional expansion by prominent market players.
The
Middle East & Africa region holds the least market share among all the
mentioned regions.
Competitive Landscape
The
global lupus market holds a number of
noteworthy players, including Merck KGaA, Cadila Healthcare, Mylan N.V., F.
Hoffmann-La Roche AG, Aurinia Pharmaceuticals, Inc., GlaxoSmithKline PLC, Eli
Lily and Company, Pfizer, Inc., Bristol-Myers Squibb Company, Lycera
Corporation, and Sanofi.
Dec
11th, 2018, Neovacs, a pioneer in the field of active immune therapy
for treating autoimmune diseases,
announced the continuation of its partnership with Centurion Pharma in Lupus
(SLE). This is based on the study results of the Phase IIb trial with IFNalpha Kinoid.
No comments:
Post a Comment